Wall Street Zen Upgrades Immix Biopharma (NASDAQ:IMMX) to Hold

Immix Biopharma (NASDAQ:IMMX) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other brokerages have also recently commented on IMMX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immix Biopharma in a research report on Thursday, January 22nd. Mizuho began coverage on shares of Immix Biopharma in a research note on Monday, February 9th. They set an “outperform” rating and a $14.00 target price on the stock. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Immix Biopharma presently has a consensus rating of “Hold” and a consensus price target of $11.00.

Immix Biopharma Price Performance

Shares of Immix Biopharma stock opened at $9.29 on Friday. The stock has a market capitalization of $492.00 million, a P/E ratio of -12.06 and a beta of 0.25. The business has a 50 day simple moving average of $6.38 and a two-hundred day simple moving average of $4.50. Immix Biopharma has a 12 month low of $1.34 and a 12 month high of $9.47.

Institutional Investors Weigh In On Immix Biopharma

Hedge funds have recently modified their holdings of the company. Allworth Financial LP acquired a new position in Immix Biopharma in the 4th quarter valued at about $30,000. Mathes Company Inc. purchased a new stake in shares of Immix Biopharma during the 4th quarter valued at approximately $56,000. Balyasny Asset Management L.P. acquired a new position in Immix Biopharma in the fourth quarter valued at approximately $67,000. Kera Capital Partners Inc. acquired a new position in Immix Biopharma in the fourth quarter valued at approximately $68,000. Finally, Squarepoint Ops LLC purchased a new position in Immix Biopharma in the fourth quarter worth approximately $112,000. Hedge funds and other institutional investors own 11.26% of the company’s stock.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.